van den Bemt BJF - Search Results

1

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study).

van der Togt CJT, Verhoef LM, van den Bemt BJF, den Broeder N, Ter Heine R, den Broeder AA. van der Togt CJT, et al. Among authors: den broeder n, van den bemt bjf, den broeder aa. Ther Adv Musculoskelet Dis. 2022 Dec 12;14:1759720X221142277. doi: 10.1177/1759720X221142277. eCollection 2022. Ther Adv Musculoskelet Dis. 2022. PMID: 36533097 Free PMC article.

2

Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA.

den Broeder AA, van der Maas A, van den Bemt BJ. den Broeder AA, et al. Rheumatology (Oxford). 2010 Oct;49(10):1801-3. doi: 10.1093/rheumatology/keq060. Epub 2010 Mar 23. Rheumatology (Oxford). 2010. PMID: 20332095 No abstract available.

3

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.

van den Bemt BJ, den Broeder AA, Wolbink GJ, Hekster YA, van Riel PL, Benraad B, van den Hoogen FH. van den Bemt BJ, et al. BMC Musculoskelet Disord. 2011 Jan 13;12:12. doi: 10.1186/1471-2474-12-12. BMC Musculoskelet Disord. 2011. PMID: 21232150 Free PMC article. Clinical Trial.

4

Treatment outcomes of a Numeric Rating Scale (NRS)-guided pharmacological pain management strategy in symptomatic knee and hip osteoarthritis in daily clinical practice.

Snijders GF, van den Ende CH, van den Bemt BJ, van Riel PL, van den Hoogen FH, den Broeder AA; NOAC study group. Snijders GF, et al. Clin Exp Rheumatol. 2012 Mar-Apr;30(2):164-70. Epub 2012 Apr 13. Clin Exp Rheumatol. 2012. PMID: 22325619

5

Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study.

van der Maas A, Kievit W, van den Bemt BJ, van den Hoogen FH, van Riel PL, den Broeder AA. van der Maas A, et al. Ann Rheum Dis. 2012 Nov;71(11):1849-54. doi: 10.1136/annrheumdis-2011-200945. Epub 2012 Apr 13. Ann Rheum Dis. 2012. PMID: 22504561

6

Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis.

Zwikker H, van den Bemt B, van den Ende C, van Lankveld W, den Broeder A, van den Hoogen F, van de Mosselaar B, van Dulmen S. Zwikker H, et al. Patient Educ Couns. 2012 Oct;89(1):143-51. doi: 10.1016/j.pec.2012.07.007. Epub 2012 Aug 9. Patient Educ Couns. 2012. PMID: 22878029

7

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.

van der Maas A, van den Bemt BJ, Wolbink G, van den Hoogen FH, van Riel PL, den Broeder AA. van der Maas A, et al. BMC Musculoskelet Disord. 2012 Sep 24;13:184. doi: 10.1186/1471-2474-13-184. BMC Musculoskelet Disord. 2012. PMID: 23006627 Free PMC article.

8

Antidrug antibodies to tumour necrosis factor specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective; comment on the article by Vincent et al.

den Broeder AA, van der Maas A, van den Bemt BJ. den Broeder AA, et al. Ann Rheum Dis. 2013 Jul;72(7):e14. doi: 10.1136/annrheumdis-2013-203648. Epub 2013 Apr 12. Ann Rheum Dis. 2013. PMID: 23585517 No abstract available.

9

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis.

van den Bemt BJ, den Broeder AA, Wolbink GJ, van den Maas A, Hekster YA, van Riel PL, Benraad HB, van den Hoogen FH. van den Bemt BJ, et al. Br J Clin Pharmacol. 2013 Dec;76(6):939-45. doi: 10.1111/bcp.12142. Br J Clin Pharmacol. 2013. PMID: 23601129 Free PMC article. Clinical Trial.

10

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study.

den Broeder AA, van Herwaarden N, van der Maas A, van den Hoogen FH, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ. den Broeder AA, et al. BMC Musculoskelet Disord. 2013 Oct 24;14:299. doi: 10.1186/1471-2474-14-299. BMC Musculoskelet Disord. 2013. PMID: 24152421 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

209 results

Search Page